LNP Formulation for mRNA Therapies
Polyplus’ LipidBrick IM21.7 is designed to expand the scope of LNP usage in various therapeutic and oncology applications.
Polyplus’ LipidBrick IM21.7 is a novel cationic lipid nanoparticle (LNP) formulation for messenger RNA therapeutic and vaccine development. The formulation is designed to expand the scope of LNP usage in various therapeutic and oncology applications, as well as prophylactic vaccines.
The LipidBrick is designed to overcome current-generation ionizable lipid challenges used in current LNPs by enabling a wider in-vivo biodistribution and decreasing accumulation in the liver. Proof of concept work demonstrated that it successfully modulates the overall charge of LNPs, improving drug efficiency and formulation stability with no additional safety concerns.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Legal and Regulatory Perspectives on 3D Printing: Drug Compounding Applications
December 10th 2024This paper explores the legal and regulatory framework around 3D drug printing, particularly for personalized medicine, considering regulatory compliance, business concerns, and intellectual property rights.
